Payment overview · 2025
General Payments
$120.92
5 reported records · 5 companies
Healthcare provider profile · identity verified
Kathryn Eileen Mccloskey, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · NORFOLK, VA · NPI 1679952113
Verified facts
What the public records show
CMS Open Payments records show Kathryn Eileen Mccloskey, M.D. received $120.92 in general payments during 2025 across 5 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 27.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $33.08 | 27.4% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $27.16 | 22.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $21.21 | 17.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.74 | 17.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.73 | 15.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $120.92 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $33.08 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $27.16 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $21.21 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.74 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 287 | 129 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 234 | 126 |
| Amlodipine Besylate | Amlodipine Besylate | 192 | 98 |
| Losartan Potassium | Losartan Potassium | 161 | 74 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 141 | 85 |
| Lisinopril | Lisinopril | 141 | 69 |
| Furosemide | Furosemide | 136 | 72 |
| Gabapentin | Gabapentin | 125 | 71 |
| Metoprolol Succinate | Metoprolol Succinate | 120 | 63 |
| Carvedilol | Carvedilol | 107 | 64 |
| Eliquis | Apixaban | 104 | 22 |
| Levothyroxine Sodium | Levothyroxine Sodium | 103 | 49 |
| Pantoprazole Sodium | Pantoprazole Sodium | 102 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 101 | 58 |
| Omeprazole | Omeprazole | 93 | 59 |
| Clopidogrel | Clopidogrel Bisulfate | 90 | 41 |
| Fluticasone Propionate | Fluticasone Propionate | 88 | 61 |
| Duloxetine Hcl | Duloxetine Hcl | 81 | 46 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 80 | 23 |
| Diclofenac Sodium | Diclofenac Sodium | 79 | 57 |
| Trazodone Hcl | Trazodone Hcl | 77 | 35 |
| Metformin Hcl | Metformin Hcl | 75 | 41 |
| Montelukast Sodium | Montelukast Sodium | 73 | 45 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 65 | 34 |
| Glipizide | Glipizide | 64 | 33 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 64 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 63 | 35 |
| Hydralazine Hcl | Hydralazine Hcl | 62 | 29 |
| Potassium Chloride | Potassium Chloride | 59 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 49 | 25 |
| Tizanidine Hcl | Tizanidine Hcl | 48 | 33 |
| Mirtazapine | Mirtazapine | 47 | 27 |
| Quetiapine Fumarate | Quetiapine Fumarate | 46 | 18 |
| Allopurinol | Allopurinol | 45 | 26 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 42 | 38 |
| Warfarin Sodium | Warfarin Sodium | 42 | 11 |
| Bumetanide | Bumetanide | 41 | 25 |
| Famotidine | Famotidine | 41 | 34 |
| Metformin Hcl Er | Metformin Hcl | 41 | 23 |
| Sertraline Hcl | Sertraline Hcl | 41 | 25 |
| Methylprednisolone | Methylprednisolone | 39 | 33 |
| Cephalexin | Cephalexin | 37 | 29 |
| Alendronate Sodium | Alendronate Sodium | 35 | 20 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 35 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 35 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 35 | 14 |
| Spironolactone | Spironolactone | 35 | 22 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 34 | 23 |
| Buspirone Hcl | Buspirone Hcl | 34 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | 18 |
| Ozempic | Semaglutide | 34 | suppressed |
| Finasteride | Finasteride | 33 | 21 |
| Prednisone | Prednisone | 31 | 24 |
| Levetiracetam | Levetiracetam | 30 | 15 |
| Simvastatin | Simvastatin | 29 | 18 |
| Atenolol | Atenolol | 28 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | 16 |
| Midodrine Hcl | Midodrine Hcl | 28 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 27 | suppressed |
| Memantine Hcl | Memantine Hcl | 27 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | 17 |
| Fluconazole | Fluconazole | 26 | 17 |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 26 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 25 | 11 |
| Ibu | Ibuprofen | 25 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 24 | 13 |
| Naproxen | Naproxen | 24 | 12 |
| Nifedipine Er | Nifedipine | 24 | 14 |
| Nitroglycerin | Nitroglycerin | 24 | 17 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 23 | 20 |
| Baclofen | Baclofen | 22 | 15 |
| Donepezil Hcl | Donepezil Hcl | 22 | suppressed |
| Ibuprofen | Ibuprofen | 22 | 19 |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 21 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 20 | 14 |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Lyumjev Kwikpen U-100 | Insulin Lispro-Aabc | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | 12 |
| Azithromycin | Azithromycin | 18 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | suppressed |
| Jardiance | Empagliflozin | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 17 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Meloxicam | Meloxicam | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Methocarbamol | Methocarbamol | 15 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 15 | 12 |
| Sucralfate | Sucralfate | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Etravirine | Etravirine | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Triumeq | Abacavir/Dolutegravir/Lamivudi | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | 11 |
| Pregabalin | Pregabalin | 11 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $120.92 · 5 records | Otsuka America Pharmaceutical, Inc. | Cologuard Collection Kit, FARXIGA, JARDIANCE, Korlym, REXULTI | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error